MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
February 3, 2011
Brian Orelli
Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes. mark for My Articles similar articles
The Motley Fool
July 23, 2008
Brian Orelli
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. mark for My Articles similar articles
The Motley Fool
April 23, 2008
Brian Orelli
Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up. mark for My Articles similar articles
The Motley Fool
July 29, 2011
Brian Orelli
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? mark for My Articles similar articles
The Motley Fool
April 21, 2009
Brian Orelli
Boston Scientific Rebuilds Whether the company is a value or a value trap depends on how well the rebuilding goes this year. mark for My Articles similar articles
The Motley Fool
January 29, 2009
Brian Orelli
No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed. mark for My Articles similar articles
The Motley Fool
December 5, 2005
Stephen D. Simpson
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. mark for My Articles similar articles
The Motley Fool
February 5, 2008
Brian Orelli
Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter. mark for My Articles similar articles
The Motley Fool
October 20, 2009
Robert Steyer
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. mark for My Articles similar articles
The Motley Fool
October 13, 2008
Brian Orelli
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. mark for My Articles similar articles
The Motley Fool
April 24, 2007
Ryan Fuhrmann
Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock. mark for My Articles similar articles
The Motley Fool
July 23, 2007
Ryan Fuhrmann
Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 23, 2008
Brian Orelli
Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter. mark for My Articles similar articles
The Motley Fool
July 21, 2010
Brian Orelli
Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now. mark for My Articles similar articles
The Motley Fool
May 29, 2008
Brian Orelli
Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific. mark for My Articles similar articles
The Motley Fool
February 1, 2010
Brian Orelli
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. mark for My Articles similar articles
The Motley Fool
April 9, 2010
Brian Orelli
Is Boston Scientific Turning It Around? Selling off a pair of units could help. mark for My Articles similar articles
The Motley Fool
February 5, 2007
Ryan Fuhrmann
Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note. mark for My Articles similar articles
The Motley Fool
May 28, 2009
Brian Orelli
Boston Scientific Back in an Atomic Way Can its tiny stent save the day? mark for My Articles similar articles
The Motley Fool
November 24, 2009
Brian Orelli
52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs. mark for My Articles similar articles
The Motley Fool
September 14, 2011
Brian Orelli
How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible. mark for My Articles similar articles
The Motley Fool
February 17, 2009
Brian Orelli
Investors Heart Medtronic The leaner company is more lovable. mark for My Articles similar articles
The Motley Fool
August 18, 2008
Brian Orelli
Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%. mark for My Articles similar articles
The Motley Fool
February 7, 2006
Stephen D. Simpson
Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again. mark for My Articles similar articles
The Motley Fool
April 19, 2005
Stephen D. Simpson
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. mark for My Articles similar articles
The Motley Fool
January 11, 2008
Brian Orelli
Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008. mark for My Articles similar articles
The Motley Fool
May 14, 2008
Brian Orelli
Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial. mark for My Articles similar articles
The Motley Fool
May 25, 2010
Brian Orelli
Medtronic Gets Tossed Out With the Bathwater A bad day to report good news. mark for My Articles similar articles
The Motley Fool
September 26, 2005
Stephen D. Simpson
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? mark for My Articles similar articles
The Motley Fool
July 31, 2006
Stephen D. Simpson
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. mark for My Articles similar articles
The Motley Fool
August 12, 2010
Brian Orelli
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. mark for My Articles similar articles
The Motley Fool
November 9, 2009
Brian Orelli
Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. mark for My Articles similar articles
The Motley Fool
August 20, 2008
Brian Orelli
Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market. mark for My Articles similar articles
The Motley Fool
July 7, 2008
Brian Orelli
And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V. mark for My Articles similar articles
The Motley Fool
May 28, 2004
W.D. Crotty
Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability. mark for My Articles similar articles
The Motley Fool
August 25, 2009
Brian Orelli
Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again. mark for My Articles similar articles
The Motley Fool
September 30, 2009
Brian Orelli
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. mark for My Articles similar articles
The Motley Fool
May 27, 2004
Jeff Hwang
Guidant's Stent Stumble Yesterday, Guidant said that a regulatory filing for marketing approval of its Champion stainless steel stent could be delayed up to six months due to "issues" that may result in "manufacturing process modifications and/or stent design changes." mark for My Articles similar articles
The Motley Fool
October 14, 2005
Stephen D. Simpson
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. mark for My Articles similar articles
The Motley Fool
April 27, 2010
Brian Orelli
Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless. mark for My Articles similar articles
The Motley Fool
January 6, 2005
Stephen D. Simpson
Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past. mark for My Articles similar articles
The Motley Fool
December 31, 2007
Brian Orelli
Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed. mark for My Articles similar articles
The Motley Fool
January 17, 2006
Stephen D. Simpson
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. mark for My Articles similar articles
The Motley Fool
September 29, 2010
Brian Orelli
Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around. mark for My Articles similar articles
The Motley Fool
November 11, 2009
Jim Mueller
This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions. mark for My Articles similar articles
The Motley Fool
January 25, 2006
Stephen D. Simpson
Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note. mark for My Articles similar articles
The Motley Fool
February 24, 2004
Alyce Lomax
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? mark for My Articles similar articles
The Motley Fool
August 6, 2004
Jeff Hwang
Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share? mark for My Articles similar articles
The Motley Fool
July 19, 2005
Stephen D. Simpson
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. mark for My Articles similar articles